Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/ Pharmacodynamics and Efficacy of BR1733 Monotherapy in Subjects With Advanced Cancers

NCT05749549 is registered in ClinicalTrials.gov with Shanghai Blueray Biopharma Co., Ltd. as lead sponsor.

NCT NCT05749549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05749549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/ Pharmacodynamics and Efficacy of BR1733 Monotherapy in Subjects With Advanced Cancers
Lead sponsor
Shanghai Blueray Biopharma Co., Ltd.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 19, 2023
Completion date
May 31, 2026
Enrollment
191 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, diffuse large b cell lymphoma, follicular lymphoma, peripheral t cell lymphoma